[go: up one dir, main page]

WO2007057399A3 - Treatment of cancer with indole derivatives - Google Patents

Treatment of cancer with indole derivatives Download PDF

Info

Publication number
WO2007057399A3
WO2007057399A3 PCT/EP2006/068461 EP2006068461W WO2007057399A3 WO 2007057399 A3 WO2007057399 A3 WO 2007057399A3 EP 2006068461 W EP2006068461 W EP 2006068461W WO 2007057399 A3 WO2007057399 A3 WO 2007057399A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
indole derivatives
indolinones
mek1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/068461
Other languages
French (fr)
Other versions
WO2007057399A2 (en
Inventor
Wolfgang Sommergruber
Norbert Kraut
Norbert Schweifer
Wolfgang Rettig
Frank Hilberg
Flavio Solca
Martin Steegmaier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of WO2007057399A2 publication Critical patent/WO2007057399A2/en
Publication of WO2007057399A3 publication Critical patent/WO2007057399A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is based on the finding that indolinones are useful for the therapy of diseases which result from aberrant activity of a kinase selected from the group comprising AXL, FLT3, MEK1, and RET.
PCT/EP2006/068461 2005-11-15 2006-11-14 Treatment of cancer with indole derivatives Ceased WO2007057399A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05110778 2005-11-15
EP05110778.7 2005-11-15

Publications (2)

Publication Number Publication Date
WO2007057399A2 WO2007057399A2 (en) 2007-05-24
WO2007057399A3 true WO2007057399A3 (en) 2007-08-30

Family

ID=35695754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/068461 Ceased WO2007057399A2 (en) 2005-11-15 2006-11-14 Treatment of cancer with indole derivatives

Country Status (1)

Country Link
WO (1) WO2007057399A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851434B2 (en) 2017-01-18 2023-12-26 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009062122A1 (en) * 2007-11-09 2009-05-14 John Wayne Cancer Institute Utility of ret mutant in diagnosis and treatment of melanoma
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
CN102994616B (en) * 2011-09-13 2014-06-18 益善生物技术股份有限公司 MEK1 gene mutation detection specificity primer and liquid chip thereof
NZ627586A (en) 2012-01-31 2016-08-26 Daiichi Sankyo Co Ltd Pyridone derivatives
TWI690525B (en) 2014-07-07 2020-04-11 日商第一三共股份有限公司 Pyridone derivatives containing tetrahydropyranylmethyl group and use thereof
BR112017010141A2 (en) 2014-11-16 2018-03-06 Array Biopharma, Inc. CRYSTALLINE FORM OF (S) -N- (5- ((R) -2- (2,5-DIFLUOROFENYL) -PIRROLIDIN-1-IL) -PIRAZOLO [1,5- A] PYRIMIDIN-3-IL -3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE
KR20180041135A (en) 2015-07-16 2018-04-23 어레이 바이오파마 인크. A pyrazolo [1,5-a] pyridine compound substituted as a RET kinase inhibitor
AU2016344058A1 (en) 2015-10-26 2018-05-17 Array Biopharma Inc. Point mutations in Trk inhibitor-resistant cancer and methods relating to the same
JP6885390B2 (en) 2016-02-26 2021-06-16 小野薬品工業株式会社 A drug for the treatment of cancer, which comprises administering a combination of an Axl inhibitor and an immune checkpoint inhibitor.
SG11201808676RA (en) 2016-04-04 2018-11-29 Loxo Oncology Inc Methods of treating pediatric cancers
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
CN109414442B (en) 2016-04-04 2024-03-29 洛克索肿瘤学股份有限公司 Liquid preparation of compound
US11214571B2 (en) 2016-05-18 2022-01-04 Array Biopharma Inc. Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
JP7156287B2 (en) 2017-08-23 2022-10-19 小野薬品工業株式会社 Cancer therapeutic agent containing an Axl inhibitor as an active ingredient
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TWI876442B (en) 2017-10-10 2025-03-11 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
JP7223998B2 (en) 2017-10-13 2023-02-17 小野薬品工業株式会社 Solid cancer therapeutic agent containing an Axl inhibitor as an active ingredient
TW201932464A (en) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 Substituted pyrazolyl[4,3-C]pyridine compounds as RET kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN119841763A (en) * 2024-11-08 2025-04-18 广州湾区生物医药研究院 Halogenated indolone compound, preparation method and application thereof, halogenated indolone derivative and application thereof, pharmaceutical composition and application thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052869A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Kg Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes
WO2000073297A1 (en) * 1999-05-27 2000-12-07 Boehringer Ingelheim Pharma Kg Substituted indolinone as tyrosine kinase inhibitors
WO2002036564A1 (en) * 2000-11-01 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sulfonylamino substituted 3-(aminomethylide)-2-indolinones as cell proliferation inhibitors
WO2004009546A1 (en) * 2002-07-23 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indoline derivatives substituted in position 6, production and use thereof as medicaments
WO2004009547A1 (en) * 2002-07-23 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indoline derivatives substituted in position 6, production and use thereof as medicaments
WO2004017948A2 (en) * 2002-08-16 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of lck inhibitor for treatment of immunologic diseases
WO2006067175A1 (en) * 2004-12-24 2006-06-29 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
WO2007054551A1 (en) * 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052869A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Kg Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes
WO2000073297A1 (en) * 1999-05-27 2000-12-07 Boehringer Ingelheim Pharma Kg Substituted indolinone as tyrosine kinase inhibitors
WO2002036564A1 (en) * 2000-11-01 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sulfonylamino substituted 3-(aminomethylide)-2-indolinones as cell proliferation inhibitors
WO2004009546A1 (en) * 2002-07-23 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indoline derivatives substituted in position 6, production and use thereof as medicaments
WO2004009547A1 (en) * 2002-07-23 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indoline derivatives substituted in position 6, production and use thereof as medicaments
WO2004017948A2 (en) * 2002-08-16 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of lck inhibitor for treatment of immunologic diseases
WO2006067175A1 (en) * 2004-12-24 2006-06-29 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
WO2007054551A1 (en) * 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851434B2 (en) 2017-01-18 2023-12-26 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors

Also Published As

Publication number Publication date
WO2007057399A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2007057399A3 (en) Treatment of cancer with indole derivatives
UA98629C2 (en) Compounds and methods for kinase modulation
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
IN2014KN02886A (en)
NO2012017I1 (en) Benzimidazole derivative, process for its preparation, drug containing this compound and use of the compound.
LTC1830843I2 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
EA200970447A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
IS2722B (en) 1, 2, 3, 4- Tetrasetin indole for the treatment of respiratory diseases
EP2046973A4 (en) For the identification, assessment, and treatment of patients with cancer therapy
DK2054418T3 (en) Dihydrothienopyrimidines as AKT protein kinase inhibitors
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
NO20082130L (en) 3-Amino-1-arylpropylindoles and aza-substituted indoles
NL1029045A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth.
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
NO20080037L (en) Combination of Pyrimidylaminobenzamide Compounds and Imatinib for the Treatment or Prevention of Proliferative Diseases
WO2006078865A3 (en) Direct racemization of indole derivatives
WO2006075256A3 (en) 9a-carbamoyl-ϝ-aminopropyl- and 9a-thiocarbamoyl-ϝ-aminopropyl-azalides with antimalarial activity
WO2006135949A3 (en) Tumour treatment with gliotoxin derivatives
WO2004034889A3 (en) Photodynamic therapy for ocular neovascularization
WO2006079539A3 (en) Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
WO2007002087A3 (en) Cdc6s as modifiers of the pten/akt pathway and methods of use
WO2005010148A3 (en) Marks as modifiers of the pten pathway and methods of use
WO2006066923A3 (en) Indole derivatives with antitumor activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06829994

Country of ref document: EP

Kind code of ref document: A2